Circio Holding ASA (OSE:CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy and cancer vaccines, revealed on Wednesday that it has terminated the exclusive TG01 KRAS cancer vaccine licence option agreement with its Chinese partner IOVaxis Therapeutics in Greater China and Singapore due to non-payment.
Despite previously granting a payment extension, Circio terminated the agreement as IOVaxis failed to make the agreed initial payment of USD300,000.
Dr Erik Digman Wiklund, Circio's CEO, stated that the three collaborative clinical studies in the United States and European Union are proceeding unaffected.
Circio will now explore alternative partnerships for TG01 in China, leaving room for potential reactivation of discussions with IOVaxis if financial obligations are met.
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Anixa Biosciences secures US patent allowance for ovarian cancer vaccine
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
Centivax partners with Emery Pharma on universal flu vaccine
GSK receives approval from US FDA for Penmenvy 5-in-1 meningitis vaccine
hVIVO secures GBP2m contract for final stage of hMPV characterisation study
EU approves CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate
Bain Capital to acquire Mitsubishi Tanabe Pharma in USD3.3bn deal